 | |
| Names | |
|---|---|
| IUPAC name (4R,4aS,7S,7aR,12bS)-9-methoxy-7-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-ol | |
| Other names Oxicodegol; Loxicodegol; NKTR-181 | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider | |
| DrugBank | |
| KEGG | |
| UNII | |
| |
| |
| Properties | |
| C31H49NO10 | |
| Molar mass | 595.730 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Oxycodegol (also known asloxicodegol andNKTR-181) is an experimentalμ-opioid receptoragonist for the treatment of pain.[1][2] It has had success for back pain as an alternative to traditional opioids,[3] which have potential for abuse. It acts more slowly on thecentral nervous system, reducing risk for abuse and respiratory depression.[1]
